SLNO

Soleno Therapeutics develops treatments for rare genetic and metabolic disorders, with a focus on Prader-Willi syndrome. The company's lead program is VYKAT XR (diazoxide choline), an extended-release tablet that has received regulatory approval in the United States and is being evaluated for potential commercialization outside the U.S. Soleno is in the commercial and late-stage development phase, having brought at least one product to market while continuing to explore expansion opportunities internationally.

Pipeline

Catalyst Calendar